Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:ATE CVE:EMH NASDAQ:PMN NASDAQ:SVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATEAntibe TherapeuticsC$0.00C$0.15▼C$1.23C$15.64M0.19135,475 shs167,044 shsEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsPMNPromis Neurosciences$0.52-1.8%$0.59$0.38▼$1.59$27.15M-0.042.72 million shs357,099 shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.67M0.61N/AN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATEAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%EMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%PMNPromis Neurosciences-2.84%+1.62%-40.74%+5.71%-59.28%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATEAntibe TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APMNPromis Neurosciences3.2558 of 5 stars3.55.00.00.03.30.80.6SVASinovac BiotechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATEAntibe Therapeutics 0.00N/AN/AN/AEMHEmerald Health Therapeutics 0.00N/AN/AN/APMNPromis Neurosciences 3.00Buy$4.33698.04% UpsideSVASinovac Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATE, SVA, EMH, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025PMNPromis NeurosciencesLeede FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy7/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.007/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATEAntibe TherapeuticsC$9.71M0.00N/A0.61C$0.49 per share0.00EMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64PMNPromis NeurosciencesN/AN/AN/AN/A($0.01) per shareN/ASVASinovac Biotech$448.27M1.44$0.17 per share38.95$120.83 per share0.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATEAntibe Therapeutics-C$18.24M-C$0.35N/AN/AN/AN/A-52.72%-19.13%N/AEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/APMNPromis Neurosciences$2.78M-$0.21N/AN/AN/AN/A-266.69%-131.59%11/13/2025 (Estimated)SVASinovac Biotech-$99.92MN/A0.00∞N/AN/AN/AN/AN/ALatest ATE, SVA, EMH, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PMNPromis Neurosciences-$0.22-$0.29-$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATEAntibe TherapeuticsC$0.05N/AN/AN/A N/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATEAntibe Therapeutics0.2910.069.58EMHEmerald Health Therapeutics35.452.972.61PMNPromis NeurosciencesN/A0.970.97SVASinovac BiotechN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATEAntibe TherapeuticsN/AEMHEmerald Health TherapeuticsN/APMNPromis Neurosciences50.13%SVASinovac BiotechN/AInsider OwnershipCompanyInsider OwnershipATEAntibe Therapeutics7.94%EMHEmerald Health TherapeuticsN/APMNPromis Neurosciences6.11%SVASinovac Biotech12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATEAntibe Therapeutics1153.01 millionN/ANot OptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionablePMNPromis Neurosciences551.81 million48.64 millionNot OptionableSVASinovac Biotech3,26199.64 million86.89 millionOptionableATE, SVA, EMH, and PMN HeadlinesRecent News About These CompaniesSINOVAC Board Sets the Record Straight on July 8 Special Meeting of ...July 13, 2025 | morningstar.comMSINOVAC Board of Directors Provides Update on Status of US$55.00 ...July 11, 2025 | morningstar.comMSINOVAC Board Sets the Record Straight on July 8 Special Meeting of ShareholdersJuly 11, 2025 | businesswire.comSinovac Biotech’s New Board Charts Future Path with Strategic InitiativesJuly 11, 2025 | tipranks.comNewly Elected Directors of Sinovac Hold the First Board MeetingJuly 10, 2025 | financialpost.comFNewly Elected Directors of Sinovac Hold the First Board MeetingJuly 10, 2025 | businesswire.comFinal Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2 - NasdaqJuly 9, 2025 | nasdaq.comSINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former BoardJuly 9, 2025 | businesswire.comSINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend PaymentJuly 9, 2025 | businesswire.comSINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE SharesJuly 9, 2025 | businesswire.comAppeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder VoteJuly 9, 2025 | businesswire.comSinovac Biotech Retains Support from Proxy Advisors Ahead of Crucial VoteJuly 8, 2025 | tipranks.comFinal Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2July 7, 2025 | finance.yahoo.comFinal Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card “AGAINST” Misguided Proposals 1 and 2July 7, 2025 | businesswire.comFederal Court in Massachusetts Denies Vivo Capital’s Petition for Relief on SINOVACJuly 7, 2025 | finance.yahoo.comFederal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVACJuly 7, 2025 | businesswire.comLeading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in PlaceJuly 3, 2025 | businesswire.comUnited States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding SinovacJuly 2, 2025 | businesswire.comSAIF Partners: Now is Your Last Chance to Vote for Board Change at SinovacJuly 2, 2025 | businesswire.comSinovac Controlling Investors Ordered to Amend DisclosuresJuly 2, 2025 | news.bloomberglaw.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAn Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAEBy Jeffrey Neal Johnson | August 13, 2025Data Centers Create a Bull Case for These Nuclear 3 StocksBy Gabriel Osorio-Mazilli | August 14, 2025IPO Market Stays Hot With These 2 Debuting StocksBy Dan Schmidt | August 11, 2025Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging By Nathan Reiff | August 4, 2025ATE, SVA, EMH, and PMN Company DescriptionsAntibe Therapeutics TSE:ATEAntibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Emerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.Promis Neurosciences NASDAQ:PMN$0.53 -0.01 (-1.39%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Sinovac Biotech NASDAQ:SVASinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike at a Crossroads: AI Halo vs. Risks NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access